Latest news

The National Institute for Health and Care Excellence (NICE) has today (Thursday, 17th September) announced it will not allow advanced pancreatic cancer patients in England routine access to the life-extending drug Abraxane on the NHS.

Research findings into the use of an anti-diabetic drug that can be used to ‘suffocate’ pancreatic cancer stem cells have been widely reported in the media today. Here's our comment.

NHS England has today (Friday, 4th September) announced that the life-extending drug Abraxane will no longer be available to people with advanced pancreatic cancer in England through the Cancer Drugs Fund (CDF) from 4th November 2015.

The Information Services Division (ISD) Scotland has this week released data showing trends in the likely number of cases of different cancer types over a 25 year period up until 2027. Here's our comment. 

A ComRes survey of over 2,000 people, commissioned by Pancreatic Cancer UK, found that almost three quarters could not name unprompted any symptoms of the disease, which include tummy pain, weight loss, yellow skin or eyes or itchy skin and oily floating poo.